Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jennifer L. Olson & Richard J. Bold. (2018) Currently available first-line drug therapies for treating pancreatic cancer. Expert Opinion on Pharmacotherapy 19:17, pages 1927-1940.
Read now
Read now
Articles from other publishers (27)
Yu-Ting Fang, Wen-Wei Yang, Ya-Ru Niu & Yong-Kun Sun. (2023) Recent advances in targeted therapy for pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology 15:4, pages 571-595.
Crossref
Crossref
Anna P. Loboda, Leonid S. Adonin, Svetlana D. Zvereva, Dmitri Y. Guschin, Tatyana V. Korneenko, Alexandra V. Telegina, Olga K. Kondratieva, Sofia E. Frolova, Nikolay B. Pestov & Nick A. Barlev. (2023) BRCA Mutations—The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers. International Journal of Molecular Sciences 24:5, pages 4982.
Crossref
Crossref
Ada W.Y. Leung, Kent T.J. Chen, Gemma M. Ryan, Malathi Anantha, Nicole Wretham, Zeynab Nosrati, Devon Heroux, Linchuan Wang, Norman Chow, Zhongye Dai & Marcel B. Bally. (2022) DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation. Journal of Controlled Release 345, pages 75-90.
Crossref
Crossref
Joaquina Martínez-Galán, Isabel Rodriguez & Octavio Caba. (2021)
Importance of
BRCA
mutation for the current treatment of pancreatic cancer beyond maintenance
. World Journal of Gastroenterology 27:39, pages 6515-6521.
Crossref
Crossref
Kai Zimmer, Florian Kocher, Alberto Puccini & Andreas Seeber. (2021) Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives. Frontiers in Oncology 11.
Crossref
Crossref
Parnia Rahnamay Farnood, Romina Danesh Pazhooh, Zatollah Asemi & Bahman Yousefi. (2021) DNA damage response and repair in pancreatic cancer development and therapy. DNA Repair 103, pages 103116.
Crossref
Crossref
Paige T Shelemey, Carla P Amaro, Danny Ng, Vincent Falck & Vincent C Tam. (2021) Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment. BMJ Case Reports 14:5, pages e238395.
Crossref
Crossref
Guangjian Yang, Jiangxia Yin, Kai Ou, Qiang Du, Wenhao Ren, Yujing Jin, Liming Peng & Lin Yang. (2020) Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis. BMC Gastroenterology 20:1.
Crossref
Crossref
Atsushi Oba, Felix Ho, Quoc Riccardo Bao, Mohammed H. Al-Musawi, Richard D. Schulick & Marco Del Chiaro. (2020) Neoadjuvant Treatment in Pancreatic Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Suyue Zhao, Tao Fang, Li Yao, Ying Zheng, Ling Zhang & Kexiang Zhu. (2020) The efficacy and adverse effects of PARP inhibitor combined with chemotherapy compared with chemotherapy alone in the treatment of cancer patient. Medicine 99:45, pages e23040.
Crossref
Crossref
Hitendra Patel, Ryosuke Okamura, Paul Fanta, Charmi Patel, Richard B. Lanman, Victoria M. Raymond, Shumei Kato & Razelle Kurzrock. (2019) Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Xiaomeng Zhang, Ningyi Ma, Weiqiang Yao, Shuo Li & Zhigang Ren. (2019) RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer. Cancer Cell International 19:1.
Crossref
Crossref
Kun Fan, Zhiyao Fan, He Cheng, Qiuyi Huang, Chao Yang, Kaizhou Jin, Guopei Luo, Xianjun Yu & Chen Liu. (2019) Hexokinase 2 dimerization and interaction with voltage‐dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. Cancer Medicine 8:13, pages 5903-5915.
Crossref
Crossref
Ainhoa Madariaga, Stephanie Lheureux & Amit Oza. (2019) Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers 11:3, pages 416.
Crossref
Crossref
Amber Draper. (2018) Updates in pancreatic cancer: Modest gains and hopeful targets. Journal of Oncology Pharmacy Practice 25:1, pages 101-109.
Crossref
Crossref
I. A. PokataevA. S. PopovaI. S. AbramovM. A. EmelyanovaТ. V. NasedkinaL. N. LyubchenkoL. S. BazinE. V. ArtamonovaM. Yu. FedyaninS. Ph. MenshikovaS. A. Tjulandin. (2018) GERMINAL MUTATIONS IN HOMOLOGOUS RECOMBINATION GENES IN A POPULATION OF PATIENTS WITH PANCREATIC CANCER: A SINGLE CENTRE EXPERIENCE. Malignant tumours 8:3, pages 5-12.
Crossref
Crossref
Mao Li, Yu Mou, Shengzhong Hou, Dan Cao & Ang Li. (2018) Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib. Medicine 97:45, pages e13113.
Crossref
Crossref
Alex B. Blair, Vincent P. Groot, Georgios Gemenetzis, Jishu Wei, John L. Cameron, Matthew J. Weiss, Michael Goggins, Christopher L. Wolfgang, Jun Yu & Jin He. (2018) BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Journal of the American College of Surgeons 226:4, pages 630-637.e1.
Crossref
Crossref
Emily Glogowski, Kasmintan A. Schrader, Kelly L. Stratton & Kenneth Offit. 2018. The American Cancer Society's Principles of Oncology. The American Cancer Society's Principles of Oncology
45
57
.
Priya Bhosale, Veronica Cox, Silvana Faria, Sanaz Javadi, Chitra Viswanathan, Eugene Koay & Eric Tamm. (2017) Genetics of pancreatic cancer and implications for therapy. Abdominal Radiology 43:2, pages 404-414.
Crossref
Crossref
Maria Diab & Philip A. Philip. 2018. Current and Emerging Therapies in Pancreatic Cancer. Current and Emerging Therapies in Pancreatic Cancer
119
134
.
Aglaya G. Iyevleva & Evgeny N. Imyanitov. (2016) Cytotoxic and targeted therapy for hereditary cancers. Hereditary Cancer in Clinical Practice 14:1.
Crossref
Crossref
Louis de Mestier, Jean-Baptiste Danset, Cindy Neuzillet, Vinciane Rebours, J?r?me Cros, Nadem Soufir & Pascal Hammel. (2016)
Pancreatic ductal adenocarcinoma in
BRCA2
mutation carriers: Table 1
. Endocrine-Related Cancer 23:10, pages T57-T67.
Crossref
Crossref
Elena Mogilyansky, Peter Clark, Kevin Quann, Honglei Zhou, Eric Londin, Yi Jing & Isidore Rigoutsos. (2016) Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b. Frontiers in Genetics 7.
Crossref
Crossref
Marco Falasca, Minkyoung Kim & Ilaria Casari. (2016) Pancreatic cancer: Current research and future directions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1865:2, pages 123-132.
Crossref
Crossref
Yuan Xie, Yan Jiang, Xiao-Bo Yang, An-Qiang Wang, Yong-Chang Zheng, Xue-Shuai Wan, Xin-Ting Sang, Kai Wang, Da-Dong Zhang, Jia-Jia Xu, Fu-Gen Li & Hai-Tao Zhao. (2016)
Response of
BRCA1
-mutated gallbladder cancer to olaparib: A case report
. World Journal of Gastroenterology 22:46, pages 10254.
Crossref
Crossref
Javier Martinez-Useros & Jesus Garcia-Foncillas. (2016) The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. BioMed Research International 2016, pages 1-8.
Crossref
Crossref